A 3D-genomic blood test classified Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with 96 percent accuracy using 200 chromosomal conformation markers tied to immune and inflammatory pathways. The retrospective case–control study, funded by Oxford BioDynamics plc, demonstrated that chromatin architecture and immune dysregulation may contribute to ME/CFS biology, supporting further large-scale validation of this epigenetic diagnostic approach.

Source: Journal of Translational Medicine